TrialJournal of neurology2025

Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study.

Le H Hua et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.